Blood Pressure Response to the Valsalva Maneuver A Simple Bedside Test to Determine the Hemodynamic Basis of Pulmonary Hypertension by Forfia, Paul R. et al.
T
n
l
c
s
i
V
s
n
t
P
h
f
r
e
w
t
r
t
u
i
b
a
B
t
L
d
H
d
e
F
o
v
l
P
f
r
(
w
u
a
p
Journal of the American College of Cardiology Vol. 56, No. 16, 2010
© 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc.CORRESPONDENCE
Research
Correspondence Blood Pressure Response to the Valsalva Maneuver
A Simple Bedside Test to Determine the
Hemodynamic Basis of Pulmonary Hypertension
n
(
1
c
w
(
v
2
n
w
r
d
m
t
s
5
p
w
C
l
i
a
1
o
m
9
a
p
s
f
a
p
[
r
p
a

p
s
A
r
s
po the Editor: Pulmonary hypertension (PH) comprises heteroge-
eous conditions with diverse pathophysiology. Differentiating
eft-side heart disease from pulmonary vascular disease is critical.
The Valsalva maneuver involves forcible exhalation against a
losed glottis, causing increased intrathoracic pressure. The normal
ystolic blood pressure (SBP) response has 4 phases: 1) transient
ncrease with Valsalva onset; 2) normalization during sustained
alsalva; 3) dip after Valsalva release; and 4) “overshoot” several
econds later. A prompt fall in SBP during phase 2 suggests
ormal pulmonary artery wedge pressure (PAWP), whereas sus-
ained elevation denotes left-side heart congestion (1).
We hypothesized that this simple test could identify elevated
AWP among patients with PH, thus providing insight into the
emodynamic basis of PH before invasive assessment.
This study included 84 patients referred for PH consultation
rom March 2007 to July 2009 who were undergoing elective
ight-side heart catheterization and Valsalva within 90 days. We
xcluded patients with previously characterized PH and patients
ith a therapeutic intervention between Valsalva and catheteriza-
ion. The Hospital of the University of Pennsylvania institutional
eview board approved this study.
The blood pressure (BP) cuff was inflated 15 mm Hg greater
han the SBP, and the recumbent patient performed Valsalva for
p to 10 s (1). Phase 2 responses were classified as normal,
ntermediate, or square-wave (Korotkoff sounds persisting 3
eats, 4 beats but 10 s, or 10 s, respectively). Intermediate
nd square-wave responses were considered abnormal. The level of
-type natriuretic peptide (BNP) was determined (n  81) using
he AxSYM assay (Abbott Diagnostics, Abbott Park, Illinois).
ateral mitral annular E:e= was calculated in subjects with available
ata in sinus rhythm without prior mitral surgery (n  45).
emodynamic measurements were made at end expiration. Car-
iac output was measured by thermodilution in triplicate.
Unpaired t tests and Wilcoxon rank-sum tests were used to
valuate differences between groups for continuous variables.
isher exact test was performed for categorical variables. Receiver-
perating characteristic curves were plotted to define ideal cut-off
alues for BNP and the ratio of Doppler mitral inflow velocity to
ateral LV wall tissue Doppler velocity (E:e=) as predictors of
AWP 15 mm Hg. Multivariate logistic regression was per-
ormed inclusive of all univariate predictors of abnormal Valsalva
esponse with p  0.20. Analyses utilized SAS for Windows 9.1
SAS Institute, Cary, North Carolina).
The average age was 63.3  15.7 years, and 59.5% of patients
ere women. Abnormal Valsava responders were more likely to
se loop diuretics and beta-blockers and had a higher prevalence of
trial fibrillation, systemic hypertension, and kidney disease (all
 0.02). There was no difference between the abnormal and cormal Valsalva response groups in left ventricular ejection fraction
59.0% vs. 59.8%, p  0.75), or 6-min walk distance (321.7 
30.0 m vs. 278.2  116.1 m; p  0.10). Median time between
atheterization and Valsalva, blood draw, and echocardiography
as 18 days (interquartile range [IQR] 6 to 31.5 days), 20 days
IQR 8 to 33 days), and 21 days (IQR 8 to 60 days), respectively.
The PAWP (18.0 7.8, range 5 to 39 mm Hg) and pulmonary
ascular resistance (PVR) (6.8  4.4 mm Hg/l/min, range 0.8 to
2.6 mm Hg/l/min) varied widely, reflecting the diverse hemody-
amic basis of PH in our cohort. Figure 1 shows that the PAWP
as 2-fold higher in patients with abnormal versus normal Valsalva
esponse (22.5 6.6 mm Hg vs. 11.9 4.3 mm Hg; p 0.0001),
espite similar mean pulmonary artery pressure (43.4  10.4
m Hg vs. 46.2  9.9 mm Hg; p  0.2). The PVR and
ranspulmonary gradient were greater with normal Valsalva re-
ponse (8.1  4.6 mm Hg/l/min and 31.5  11.8 mm Hg vs.
.8  4.0 mm Hg/l/min and 23.7  11.5 mm Hg, respectively;
 0.01 and p 0.003, respectively), whereas right atrial pressure
as lower (9.9 4.6 mm Hg vs. 15.9 6.0 mm Hg; p 0.0001).
ardiac index was 2.4 l/min/m2 in both groups. The PAWP was
ower in the intermediate group (n 13; 18.9 6.7 mm Hg) than
n the square-wave group (n  35; 23.9  6.1 mm Hg; p  0.02),
lthough higher than with normal Valsalva (18.9 6.7 mm Hg vs.
1.9 4.3 mm Hg, respectively; p 0.0001). The PAWP was the
nly independent predictor of abnormal Valsalva response in a
ultivariate model (odds ratio per 5 mm Hg PAWP increase: 4.4,
5% confidence interval: 1.7 to 11.4; p  0.002; covariates: age,
trial fibrillation, beta-blocker, loop diuretic, kidney disease, hy-
ertension, diabetes mellitus, right atrial pressure, PVR).
Valsalva response identified PAWP 15 mm Hg with 89.4%
ensitivity, 86.1% specificity, and 86.9% accuracy. When per-
ormed on the day of catheterization, sensitivity, specificity, and
ccuracy were 100%, 85.7%, and 93.3%, respectively. Nine of 13
atients with intermediate response (positive predictive value
PPV]  69.2%) and 33 of 35 patients with square-wave Valsalva
esponse had PAWP 15 mm Hg (PPV  94.3%).
Log-transformed E:e= correlated poorly with PAWP (r  0.29,
 0.055). Using a cut-off of E:e= 7, sensitivity, specificity, and
ccuracy were 76.5%, 64.3%, and 68.9%, respectively, for PAWP
15 mm Hg. Log BNP and PAWP correlated poorly (r  0.18,
 0.12). Using a cut-off of 332 pg/ml, BNP had a sensitivity,
pecificity, and accuracy of 57.8%, 55.6%, and 56.8%, respectively.
bnormal Valsalva response predicted elevated PAWP over the
ange of BNP.
Abnormal BP response during the second phase of Valsalva is
ensitive and specific for elevated PAWP in a heterogeneous PH
opulation. This bedside maneuver outperforms BNP and echo-
ardiographic parameters in predicting elevated PAWP.
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1353JACC Vol. 56, No. 16, 2010 Correspondence
October 12, 2010:1352–6Abnormal Valsalva response results from maintained left ven-
ricular volume owing to excess pulmonary venous capacitance, and
hus should be specific to pathophysiologic states of left-side heart
ongestion. Our results confirm that elevated PVR and right-side
eart congestion only produce an abnormal Valsalva response
hen left-side heart congestion is also present (2). The PAWP was
he only independent predictor of abnormal Valsalva response.
alsalva response did not detect differences in pulmonary artery
ressure; however, patients with a normal response had approxi-
ately one-half the PAWP and nearly double the PVR as the
bnormal group, indicating PH of pulmonary arterial origin. There
ere no episodes of syncope or pre-syncope due to Valsalva,
ncluding among patients with severe PH.
The poor performance of BNP in predicting PAWP is unsur-
rising because our population includes patients with biventricular
athology (3). The E:e=, a Doppler surrogate of left atrial hyper-
ension, performed better but was also disappointing.
This simplified Valsalva method provides valuable hemody-
amic insight during initial PH evaluation. Despite demonstrated
tility in many diseases, the Valsalva maneuver is rarely applied in
ractice (1). We hope this study facilitates the use of this maneuver
s part of the integrated clinical assessment of undifferentiated PH.
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Figure 1 PAWP
Pulmonary artery wedge pressure (PAWP) by Valsalva response (n  84).
Dotted line designates PAWP  15 mm Hg. Bars indicate mean  SD.doi:10.1016/j.jacc.2010.03.095 sEFERENCES
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Letters to the Editor
ronedarone for
trial Fibrillation
ave We Expanded the
ntiarrhythmic Armamentarium?
ecently in the Journal, Singh et al. (1) emphasized the modest
fficacy of dronedarone as a rate and rhythm control agent for atrial
brillation (AF), questioned its safety, and concluded that it is not
n important clinical advance. The rate and rhythm control effects
f dronedarone have been extensively studied and consistently
emonstrated across studies and populations (2–4). Although
ronedarone is less effective against AF recurrence than amioda-
one in persistent AF (5), this was not the point of the ATHENA
A placebo-controlled, double-blind, parallel arm Trial to assess
he efficacy of dronedarone 400 mg bid for the prevention of
ardiovascular Hospitalization or death from any cause in patiENts
ith Atrial fibrillation/atrial flutter) (6). For the first time, a large,
andomized, controlled trial has shown that an antiarrhythmic
herapy can go beyond symptom control by reducing important
ardiovascular outcomes. The ATHENA trial clearly demon-
trated that dronedarone decreases its primary outcome of cardio-
ascular hospitalization or death, with consistent findings across all
mportant subgroups (6). Although the primary outcome was
riven mostly by a reduction in cardiovascular hospitalization,
onetheless, the mortality reduction was consistent with the overall
enefit. Arrhythmic deaths were reduced without evidence that
ther causes of death were increased, and the study also observed
tatistically significant reductions in cardiovascular death and
troke (7). Although these findings need to be confirmed in future
linical studies, these observed reductions in the ATHENA trial
onetheless support the general conclusion that dronedarone
rovides an important clinical benefit in patients with AF (6,7).
educing unplanned hospitalizations for AF and other cardiovas-
ular causes is not a small matter. Not only has cardiovascular
ospitalization been shown to be a strong predictor of subsequent
ortality (8), but also unplanned hospitalizations, usually through
mergency rooms, are widely acknowledged to be serious adverse
vents.
Can we rely on the results of the ATHENA trial, a global,
ulticenter, double-blind, placebo-controlled, randomized clinical
rial? Total mortality was not significantly reduced; however, the
tudy was not powered to demonstrate such a benefit. The
